Shares of Sage Therapeutics (SAGE.US) are plunging today. Company is one of the worst performing Wall Street stocks today, plunging over 20% at press time. The move lower was triggered after company released results of mid-stage study of its experimental dalzanemdor treatment for Parkinson's disease. Company said that the study failed to meet its main goal and did not show any statistically significant differences between the treatment and placebo.
Sage Therapeutics said that it does not plan any further development of dalzanemdor treatment for Parkinson's disease. Results of the Phase 2 studies in Huntington's and Alzheimer's diseases are expected in the later part of 2024.
Taking a look at Sage Therapeutics (SAGE.US) chart at D1 interval, we can see that the stock has recently plunged below the $16.50 support zone and continues to move lower. A massive plunge today pushed the stock below $11 per share for the first time in history. However, a part of the drop has been recovered and the stock trades off the daily lows now.
Source: xStation5
إفتتاح الأسواق الأمريكية : الأمل في خفض التصعيد يعزز موقف المضاربين على الصعود في وول ستريت
أرباح آبل تتجاوز توقعات وول ستريت 🚨 مبيعات آيفون أقل من التوقعات
🗽 شركات مؤشر ستاندرد آند بورز 500 التي حققت أعلى هامش ربح صافٍ منذ عام 2009 - بيانات فاكت سيت
ملخص السوق: مؤشر UK100 يرتفع بشكل صاروخي بعد تصريح بنك إنجلترا 🚀 مكاسب هائلة بعد خطاب لاغارد من البنك المركزي الأوروبي 📈
